Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Other financing activities (2018 - 2025)

Marker Therapeutics (MRKR) has disclosed Other financing activities for 9 consecutive years, with $33279.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other financing activities fell 37.57% to $33279.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $476953.0, a 40.82% increase, with the full-year FY2024 number at $245864.0, down 84.47% from a year prior.
  • Other financing activities was $33279.0 for Q3 2025 at Marker Therapeutics, up from $13986.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $1.7 million in Q2 2021 to a low of $13986.0 in Q2 2025.
  • A 5-year average of $713869.9 and a median of $604879.0 in 2023 define the central range for Other financing activities.
  • Peak YoY movement for Other financing activities: plummeted 89.65% in 2024, then skyrocketed 377.41% in 2025.
  • Marker Therapeutics' Other financing activities stood at $1.5 million in 2021, then tumbled by 51.11% to $717173.0 in 2022, then crashed by 80.01% to $143370.0 in 2023, then tumbled by 64.75% to $50544.0 in 2024, then plummeted by 34.16% to $33279.0 in 2025.
  • Per Business Quant, the three most recent readings for MRKR's Other financing activities are $33279.0 (Q3 2025), $13986.0 (Q2 2025), and $379144.0 (Q1 2025).